University of Pittsburgh Health Sciences eLearning Environment Internet-based Studies in Education and Research
Step by Step
INTRODUCTION
2016-09-13 - Medical Grand Rounds: Immune Mechanisms in the Tumor Microenvironment & The 4th modality has arrived - Immunotherapy for Cancer
QUIZ
EVALUATION
CERTIFICATE
INTRODUCTION
Credit Hours: CME 1.00
Target Audience:
Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.
Educational Objectives:
Presentation Topics
Upon completion of this activity, participants should be able to:
- Evaluate immune system cells and targets that mediate tumor escape and tumor progression.
- Recognize therapeutic strategies targeting suppressive cells and receptor pathways to reverse immune escape.
- Assess initial efficacy data from recent clinical trials of cancer immunotherapy.
Presentation Topics
Title:  Immune Mechanisms in the Tumor Microenvironment
Presenter:  Dario Vignali, PhD
Title:  The 4th modality has arrived - Immunotherapy for Cancer
Presenter:  Robert L. Ferris, MD, PhD
Suggested Additional Reading:
- JI-CE (2002)169:5392
- JI (2005) 174:688
- EMBOJ (2007) 26:494.
- Nature (2007) 450:566
- JI (2009) 182:6121
- Nature Immunology (2010) 11:1093
- Nature Immunology (2012) 13:290.
- Nature (2013) 501:252.
- Vignali et al (2008) Nature Reviews Immunology 8, 523.
- Galon et al. Science,2006;313:1960-1964
- Mellman I et al. Nature,2011;480:480-489.
Authors:
Dario Vignali, PhD
—
Professor & Vice Chair of Immunology
Co-Leader of the Cancer Immunology Program
Co-Director of the Tumor Microenvironment Center University of Pittsburgh Department of Immunology
Dr. Vignali receives grant/research support, Potenza Therapeutics, Tizona Therapeutics. A Consultant with Potenza Therapeutics, Tizona Therapeutics, Oncorus, Pieris, Moderna, Opexa and stockholder with Potenza Therapeutics, Tizona Therapeutics and Oncorus.
Dr. Vignali receives grant/research support, Potenza Therapeutics, Tizona Therapeutics. A Consultant with Potenza Therapeutics, Tizona Therapeutics, Oncorus, Pieris, Moderna, Opexa and stockholder with Potenza Therapeutics, Tizona Therapeutics and Oncorus.
Robert L. Ferris, MD, PhD
—
UPMC Endowed Professor and Chief, Division of Head and Neck Surgery, Department of Otolaryngology
Professor of Immunology and Radiation Oncology
Co-leader, Cancer Immunology Program
Dr. Ferris receives grant/research support from Astra-Zeneca; BMS; Merck; VentiRx Pharmaceuticals. He also a member of the Advisory Board for Astra-Zeneca/MedImmune; BMS; Lilly; Merck; Pfizer.
Dr. Ferris receives grant/research support from Astra-Zeneca; BMS; Merck; VentiRx Pharmaceuticals. He also a member of the Advisory Board for Astra-Zeneca/MedImmune; BMS; Lilly; Merck; Pfizer.
No other members of the planning committee, speakers, presenters,
authors, content reviewers and/or anyone else in a position to
control the content of this education activity have relevant
financial relationships with any companies whose primary business
is producing, marketing, selling, re-selling, or distributing
healthcare products used by or on patients.
The University of Pittsburgh is an affirmative action, equal opportunity institution.